Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18, either sex~* Histologically confirmed stage IV nasopharyngeal cancer~* One bone metastasis at least confirmed by imaging~* without chemotherapy or radiotherapy after bone metastasis~* Life expectancy \> 6 M~* ECOG \<= 2~* Adequate bone marrow reserve (WBC \> 3.5 x 109/L, Neutrophile \> 1.5 x 109/L, Platelet 100 x 109/L, Hb \> 90 g/L)~* Serum creatinine\< 2.0 mg/dL (\< 1.5 times the upper limit of the normal range for the laboratory of the study center)~* Signed ICF~Exclusion Criteria:~* Women who are pregnant or in lactation~* Patients with hyperostosis~* Systemic treatment for another cancer within the year prior to study entry~* Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy~* Initial serum creatinine \>265 micromol/L and/or progressive renal disease~* Known hypersensitivity to any of the study drugs or to drugs with similar chemical structures~* Use of investigational agents within 28 days of the Baseline visit, or participating simultaneously in any other clinical studies~* Severe co-morbidity of any type that may interfere with assessment of the patient for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Test Group (Type: EXPERIMENTAL): Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy.
- Contorl Group (Type: NO_INTERVENTION): Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).